## BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution

Integration of BD Phoenix™ Automated Microbiology System, BDXpert™ System and BD Synapsys™ Informatics Solution Supports Accurate Detection of Antimicrobial Resistance

**FRANKLIN LAKES**, **N.J.** (**April 9**, **2025**) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for BD Phoenix<sup>™</sup> M50 and BDXpert<sup>™</sup> System on the BD Synapsys<sup>™</sup> Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR).

BDXpert<sup>TM</sup> is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix<sup>TM</sup> M50 Automated Microbiology System, further enhancing its capabilities. By integrating with the BD Synapsys<sup>TM</sup> Informatics Solution, this system aids laboratorians in addressing ongoing challenges related to understaffing, increased testing demands and evolving susceptibility testing standards by helping streamline data management, helping reduce the potential for errors, and providing the delivery of critical test results and accurate information to clinicians.

"Bacterial AMR contributes to nearly five million deaths each year around the world," said Nikos Pavlidis, worldwide president, BD Diagnostic Solutions. "Rapid and precise ID/AST results lead to timely and appropriate treatment, helping reduce the spread of resistant infections and ensuring the right medication is used to combat the infection."

The BDXpert™ system, when integrated with the cutting-edge technology of BD Synapsys™ and the BD Phoenix™ M50 automated system, offers a significant advancement in diagnostic microbiology, helping provide accuracy and efficiency to support clinical microbiology laboratories.

The integrated BDXpert™ system on BD Synapsys™ will be showcased at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress from April 11-15, in Vienna, Austria, booth C55.

## **About BD**

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton\_dickinson.

## Contacts:

Media: Investors: Troy Kirkpatrick Adam Reiffe

VP, Public Relations Sr. Director, Investor Relations

858.617.2361 201.847.6927 <a href="mailto:troy.kirkpatrick@bd.com">troy.kirkpatrick@bd.com</a> adam.reiffe@bd.com

Additional assets available online: Additional assets available online: Additional assets available online:

https://news.bd.com/2025-04-09-BD-Receives-FDA-510-k-Clearance-for-Advanced-Microbiology-Solution